1 / 30

IN THE NAME OF GOD

IN THE NAME OF GOD. DELAYED PUBERTY . Puberty leads to sexual maturation and reproductive capability. It requires an intact Hypothalamic –pituitary– gonadal (HPG).

tamber
Download Presentation

IN THE NAME OF GOD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IN THE NAME OF GOD

  2. DELAYED PUBERTY

  3. Puberty leads to sexual maturation and reproductive capability. It requires an intact Hypothalamic –pituitary–gonadal (HPG). • GnRH stimulates the secretion of luteinizing hormone and follicle-stimulating hormone (FSH), which then stimulate gonadal maturation and sex steroid production.

  4. Delayed puberty is defined as the absence of testicular enlargement in boys or breast development in girls at an age that is 2 to 2.5 SD later than the population mean (traditionally, the age of 14 years in boys and 13 years in girls).

  5. Delayed puberty occurs in approximately 3% of children. • Constitutional delay in growth and puberty (CDGP) is more common in boys than in girls.

  6. Late puberty can affect psychosocial well-being, and patients, families, and practitioners are often concerned that it may affect adult stature.

  7. Constitutional delay of growth and puberty (CDGP) is the single most common cause of delayed puberty in both sexes, it can be diagnosed only after underlying conditions have been ruled out. • 65% of boys and 30% of girls with delayed puberty had CDGP.

  8. The cause of CDGP is unknown, but it has a strong genetic basis. • It has been estimated that 50 to 80% of variation in the timing of puberty in humans is due to genetic factors, and 50 to 75% of patients with CDGP have a family history of delayed puberty. • The inheritance of CDGP is variable but most often is consistent with an autosomal dominant pattern.

  9. The differential diagnosis of CDGP can be divided into three main categories: • 1- hypergonadotropichypogonadism (characterized by elevated levels of luteinizing hormone and FSH owing to the lack of negative feedback from the gonads) • 2- permanent hypogonadotropichypogonadism (characterized by low levels of luteinizing hormone and FSH owing to hypothalamic or pituitary disorders) • 3-transienthypogonadotropic hypogonadism (functional hypogonadotropichypogonadism), in which pubertal delay is caused by delayed maturation of the HPG axis secondary to an underlying condition.

  10. First-Line Evaluation • The aim of initial evaluation is to rule out underlying disorders causing delayed puberty.

  11. Eventual normal progression of puberty verifies the diagnosis of CDGP, whereas absent or slow development or cessation of development after onset is consistent with permanent hypogonadism.

  12. Family History • A family history, including childhood growth patterns and age at pubertal onset of the parents, should be obtained. • Delayed puberty in a parent or sibling followed by spontaneous onset of puberty suggests CDGP.

  13. Family History • Patients and their parents should be questioned about a history or symptoms of chronic disease, with emphasis on specific disorders (celiac disease, thyroid disease, and anorexia) that may cause temporary delay of puberty (functional hypogonadotropichypogonadism), as well as medication use, nutritional status, and psychosocial functioning.

  14. Delayed cognitive development associated with obesity or dysmorphic features may suggest an underlying genetic syndrome. • Bilateral cryptorchidism or a small penis at birth and hyposmia or anosmia may suggest hypogonadotropichypogonadism. • A history of chemotherapy or radiotherapy may indicate primary gonadal failure.

  15. Physical Examination • Previous height and weightmeasurements should be obtained.

  16. Bone-Age Radiography • A delay in bone age is characteristic but not diagnostic of CDGP and also may occur in patients with chronic illness, hypogonadotropichypogonadism, or gonadal failure. • A bone-age delay of >2 yr has been used as a criterion for CDGP but is nonspecific.

  17. Biochemical analyses • complete blood count, erythrocyte sedimentation rate, creatinine, electrolytes, bicarbonate, alkaline phosphatase, albumin, thyrotropin, and free thyroxine. • Additional testing may be necessary on the basis of family history and symptoms and signs, including screening for celiac disease and inflammatory bowel disease.

  18. Hormone Measurements • Serum follicle-stimulating hormone • Serum luteinizing hormone • Testosterone and estradiol • Basal levels of luteinizing hormone and FSH are low in patients with CDGP or hypogonadotropichypogonadism, whereas such levels are usually elevated in those with gonadal failure.

  19. Hormone Measurements • Insulin-like growth factor 1 (IGF-1) • IGF-1 must be interpreted carefully because levels are often low for chronologic age but within the normal range for bone age. • Thyroid -function test are routinely obtained.

  20. Brain Imaging Brain magnetic resonance imaging (MRI) is indicated when there are signs or symptoms to suggest a lesion in the central nervous system. • Although some clinicians routinely perform brain imaging, a reasonable strategy is to defer such evaluation until the age of 15 years, at which point many patients with CDGP will have spontaneously begun puberty and will require no further evaluation.

  21. Second-Line Evaluation • Gonadotropin-releasing hormone test • Human chorionic gonadotropin test • Serum inhibin B • Serum prolactin • Brain magnetic resonance imaging • Genetic testing

  22. No test can reliably distinguish CDGP from isolated hypogonadotropichypogonadism. Observation usually resolves this problem; isolated hypogonadotropichypogonadism is diagnosed if endogenous puberty has not begun by the age of 18 years.

  23. Treatment of patients with CDGP • The options for management of CDGP include expectant observation or therapy with low-dose testosterone (in boys) or estrogen (in girls).

  24. Boys • Testosterone is not recommended before 14 yr of age; • initial dose 50–100 mg every 4 wk for 3 to 6 mo; repeated treatment with 25-to-50-mg increment(not exceeding 100 mg) • high doses can cause premature epiphyseal closure; not for use in boys with a bone age of <10 yr

  25. Testosterone • All administered by intramuscular injection • local side effects: pain, erythema, inflammatory reaction, and sterile abscess; priapism can occur in patients with sickle cell disease • Erythrocytosis, weight gain, prostate hyperplasia

  26. Girls • Ethinylestradiol • Initial dose, 2 μg daily; increase to 5 μg daily after 6–12 mo; • Conjugated equine estrogens • Initial dose, 0.1625 mg daily for 6–12 mo with subsequent adjustment to 0.325 mg daily;

  27. Girls • Progestin (oral) usually necessary only if estrogen treatment continues longer than 12 months.

  28. When treatment is given, the goals are to induce the appearance of secondary sexual characteristics or the acceleration of growth.

  29. The routine use of growth hormone, anabolic steroids, or aromatase inhibitors is not recommended.

  30. THANKS FOR YOUR ATTENTION

More Related